Fulcrum Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Fulcrum Therapeutics, Inc. | FULC - NASDAQ |
$16.00-$18.00 | $16.00 | $14.50 | 4.5 million | 7/18/2019 |
| Morgan Stanley, BofA Merrill Lynch, SVB Leerink | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-06-21 Terms Added 2019-07-08 | ||||||
Fulcrum Therapeutics, Inc. Quote & Chart - Click for current quote - FULC
IPO Boutique aggregates information on public companies and private companies, such as "FULC" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Fulcrum Therapeutics, Inc. (adapted from Fulcrum Therapeutics, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "FULC" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.